![Ran Weinstock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ran Weinstock
Nessuna posizione attualmente
Profilo
Ran Weinstock served as an Independent Director at Bioblast Pharma Ltd.
He completed his undergraduate degree at Tel-Aviv University and his graduate degree at Bar-Ilan University and Netanya Academic College.
Precedenti posizioni note di Ran Weinstock
Società | Posizione | Fine |
---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Direttore/Membro del Consiglio | - |
Formazione di Ran Weinstock
Tel-Aviv University | Undergraduate Degree |
Netanya Academic College | Graduate Degree |
Bar-Ilan University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Borsa valori
- Insiders
- Ran Weinstock